Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGMS IGM Biosciences	$1.36 +2.7%	$1.23	$0.92 ▼ $22.50	$81.00M	0.48	454,242 shs	458,848 shs
IMUX Immunic	$0.74 +4.1%	$0.89	$0.56 ▼ $2.11	$71.10M	1.49	965,330 shs	449,673 shs
INCR InterCure	$1.53 +3.0%	$1.53	$1.17 ▼ $2.62	$69.49M	1.18	17,574 shs	17,733 shs
PIRS Pieris Pharmaceuticals	$13.60	$15.17	$6.20 ▼ $18.68	$17.95M	0.61	84,991 shs	51,728 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGMS IGM Biosciences	+2.33%	+9.09%	+4.76%	+13.79%	-79.38%
IMUX Immunic	+3.27%	+1.67%	+1.86%	-32.10%	-38.00%
INCR InterCure	0.00%	0.00%	-6.92%	+10.44%	-27.80%
PIRS Pieris Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+58.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IGMS IGM Biosciences	4.4197 of 5 stars	3.0	4.0	0.0	4.6	1.9	3.3	0.6
IMUX Immunic	2.6221 of 5 stars	3.6	1.0	0.0	0.0	2.7	2.5	0.6
INCR InterCure	0.9105 of 5 stars	0.0	5.0	0.0	0.0	2.0	0.0	0.6
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IGMS IGM Biosciences	1.90	Reduce	$5.50	305.90% Upside
IMUX Immunic	3.25	Buy	$11.60	1,463.34% Upside
INCR InterCure	0.00	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PIRS, IGMS, INCR, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/16/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/15/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IGMS IGM Biosciences	$2.68M	30.22	N/A	N/A	$0.82 per share	1.65
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
INCR InterCure	$64.55M	1.08	N/A	N/A	$2.36 per share	0.65
PIRS Pieris Pharmaceuticals	$42.81M	0.42	N/A	N/A	$21.66 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-7,417.79%	-317.97%	-71.43%	8/13/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
PIRS Pieris Pharmaceuticals	-$24.54M	-$12.10	N/A	∞	N/A	-39.71%	-80.93%	-59.55%	N/A

Latest PIRS, IGMS, INCR, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IGMS IGM Biosciences	N/A	5.71	5.71
IMUX Immunic	N/A	0.74	0.74
INCR InterCure	0.34	1.73	1.18
PIRS Pieris Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IGMS IGM Biosciences	42.79%
IMUX Immunic	51.82%
INCR InterCure	8.34%
PIRS Pieris Pharmaceuticals	40.11%

Insider Ownership

Company	Insider Ownership
IGMS IGM Biosciences	57.00%
IMUX Immunic	4.60%
INCR InterCure	0.24%
PIRS Pieris Pharmaceuticals	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IGMS IGM Biosciences	190	59.78 million	25.70 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable
INCR InterCure	350	45.57 million	45.46 million	Optionable
PIRS Pieris Pharmaceuticals	140	1.32 million	1.24 million	Optionable

PIRS, IGMS, INCR, and IMUX Headlines

Recent News About These Companies

Pieris Pharmaceuticals Inc

April 18, 2025 | money.usnews.com

Palvella Therapeutics Inc (PVLA)

December 27, 2024 | investing.com

Main Line biotech firm completes reverse merger, raises $78.9 million

December 17, 2024 | bizjournals.com

One new option listing and one option delisting on December 16th

December 17, 2024 | markets.businessinsider.com

Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments

December 14, 2024 | msn.com

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

December 14, 2024 | markets.businessinsider.com

(PIRS) Trading Report

November 27, 2024 | news.stocktradersdaily.comN

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

November 20, 2024 | businesswire.com

How To Trade (PIRS)

November 17, 2024 | news.stocktradersdaily.comN

Pieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trial

November 7, 2024 | markets.businessinsider.com

(PIRS) Investment Analysis and Advice

November 6, 2024 | news.stocktradersdaily.comN

Pieris loses Servier as partner for cancer immunotherapies

October 29, 2024 | pharmaphorum.comP

(PIRS) Technical Data

October 26, 2024 | news.stocktradersdaily.comN

Aridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News Summary

October 19, 2024 | benzinga.com

Learn to Evaluate (PIRS) using the Charts

October 16, 2024 | news.stocktradersdaily.comN

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

October 15, 2024 | globenewswire.com

(PIRS) Trading Signals

October 7, 2024 | news.stocktradersdaily.comN

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

October 3, 2024 | globenewswire.com

Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

Pieris Pharmaceuticals Inc.

September 24, 2024 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
New Catalysts to Drive NVIDIA’s Stock Price Even Higher
By Thomas Hughes | June 16, 2025
View New Catalysts to Drive NVIDIA’s Stock Price Even Higher
Marvell's New AI Chip Deals Capture Wall Street’s Attention
By Jeffrey Neal Johnson | June 21, 2025
View Marvell's New AI Chip Deals Capture Wall Street’s Attention
Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
By Thomas Hughes | June 18, 2025
View Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
By Leo Miller | June 10, 2025
View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway

PIRS, IGMS, INCR, and IMUX Company Descriptions

IGM Biosciences NASDAQ:IGMS

$1.36 +0.04 (+2.65%)

As of 12:02 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Immunic NASDAQ:IMUX

$0.74 +0.03 (+4.07%)

As of 12:02 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

InterCure NASDAQ:INCR

$1.52 +0.05 (+3.04%)

As of 11:18 AM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Pieris Pharmaceuticals NASDAQ:PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time